Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jun 4, 2018
Company News

CStone gains China rights to Blueprint programs

BioCentury | Jun 1, 2017
Financial News

Deciphera raises $52M in series C

BioCentury | Dec 2, 2016
Clinical News

Blueprint, Deciphera present Phase I GIST data

BioCentury | Aug 12, 2013
Clinical News

MEDI-575: Development discontinued

BioCentury | Dec 13, 2012
Distillery Therapeutics

Indication: Neurology

BioCentury | Nov 3, 2011
Distillery Therapeutics

Indication: Autoimmune disease

BioCentury | Nov 3, 2011
Distillery Therapeutics

Indication: Endocrine/metabolic disease

BioCentury | Feb 25, 2010
Distillery Therapeutics

Indication: Cancer

Items per page:
1 - 10 of 11
Help Center
Username
Request a Demo
Request Training
Ask a Question